Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | PREP | P48147 | 1/20 | 0.56 |
| ▸ | FAP | Q12884 | 1/20 | 0.56 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.56 |
| ▸ | MVD | P53602 | 2/20 | 0.51 |
| ▸ | REN | P00797 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PEPD | P12955 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycyl Proline SCHEMBL30051559 | 1.00 | ACE (0.62) | ACEDPP4PREPFAPDPP8 | |
| Glycyl Proline SCHEMBL155066 | 1.00 | ACE (0.62) | ACEDPP4PREPFAPDPP8 | |
| Glycyl Proline SCHEMBL4168006 | 0.98 | ACE (0.60) | ACEDPP4PREPFAPDPP8 | |
| Glycyl Proline SCHEMBL4167998 | 0.98 | ACE (0.60) | ACEDPP4PREPFAPDPP8 | |
| Glycyl Proline SCHEMBL28116179 | 0.96 | ACE (0.58) | ACEDPP4PREPFAPDPP8 | |
| Glycyl Proline SCHEMBL28116177 | 0.96 | ACE (0.58) | ACEDPP4PREPFAPDPP8 | |
| SCHEMBL31364129 | 0.94 | ACE (0.56) | ACEDPP4PREPFAPDPP8 | |
| SCHEMBL10656884 | 0.93 | ACE (0.55) | ACEDPP4PREPFAPDPP8 | |
| SCHEMBL29777459 | 0.93 | ACE (0.55) | ACEDPP4PREPFAPDPP8 | |
| Glycyl Proline SCHEMBL6660425 | 0.90 | ACE (0.53) | ACEDPP4PREPFAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1774 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743102-A1 | COLLAGEN PEPTIDE COMPOSITION AND USE THEREOF IN AMELIORATING NEUROLOGICAL CONDITIONS AND FIBROSIS | Rousselot BV (BE) | 2026-05-20 | — | — | EP | claimed |
| EP-4003288-B1 | COSMETIC COMPOSITION WITH COMBINED FILLER AND SKIN REGENERATIVE EFFECT | GIULIANI SPA (IT) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090513-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING NANOPARTICLES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4733308-A1 | FAP-TARGETING COMPOUND, AND RADIONUCLIDE-LABELED COMPLEX BASED THEREON, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2026-04-29 | — | — | EP | claimed |
| US-20260103700-A1 | REGULATION OF RAN TRANSLATION BY PKR AND EIF2A-P PATHWAYS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-04-16 | — | — | US | claimed |
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| US-12576154-B2 | Conjugates of PSMA-binding moieties with cytotoxic agents | PHILOCHEM AG (CH) | 2026-03-17 | — | — | US | claimed |
| CN-121577901-A | Urine metabolism marker combination for distinguishing benign kidney diseases from kidney cancers and application thereof | 哈尔滨脉图精准技术有限公司 | 2026-02-27 | — | — | CN | claimed |
| EP-4687866-A1 | INHIBITORS OF ETS2-ACTIVATING MOLECULES FOR THE TREATMENT OF INFLAMMATORY DISEASES | The Francis Crick Institute Limited (GB) | 2026-02-11 | — | — | EP | claimed |
| EP-0618235-A1 | Process for the synthesis of semisynthetic glycosaminoglycans containig alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN S.p.A. (IT) | 1994-10-05 | — | — | EP | claimed |
| EP-0618234-A1 | Process for the synthesis of semisynthetic glycosaminoglycans with heparin or heparan structure modified in position 2 of the alpha-L-iduronic-2-0-sulfate acid | ALFA WASSERMANN S.p.A. (IT) | 1994-10-05 | — | — | EP | claimed |
| EP-0416282-B1 | Microbiologically produced N-Acyl-L-proline-acylase, process for its production and its use | DEGUSSA (DE) | 1994-09-14 | — | — | EP | claimed |
| EP-0565863-A2 | Semi-synthetic glycosaminoglycans with heparin or heparan structure of alpha-L-iduronic-2-0-sulfate acid modified in position 2 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | claimed |
| EP-0565862-A2 | Semi-synthetic glycosaminoglycans containing alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | claimed |
| US-5219741-A | Reacting in the presence of microbiologically produced N-acyl-L-proline acylase | DEGUSSA AG (DE) | 1993-06-15 | — | — | US | claimed |
| US-5120652-A | Synthesis of proline from acyl derivatives; thermostable | DEGUSSA AG (DE) | 1992-06-09 | — | — | US | claimed |
| US-4427762-A | DEVELOPMENT WITH ALKALINE DEVELOPER MIXTURE | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1984-01-24 | — | — | US | claimed |
| EP-0082015-A1 | Method of forming an image with a photographic cuprous halide material | KONICA CORPORATION (JP) | 1983-06-22 | — | — | EP | claimed |
| US-4085207-A | AND AT LEAST ONE OF N-ACYL-L-TRYPTOPHANS AND N-ACYL-L-PROLINES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JA) | 1978-04-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576154-B2 | Conjugates of PSMA-binding moieties with cytotoxic agents | PCNA, ENPEP, PSMA3 | ACE 3096/4885DPP4 648/4885PREP 278/4885 |
| US-20260103700-A1 | REGULATION OF RAN TRANSLATION BY PKR AND EIF2A-P PATHWAYS | EIF2A, EIF2AK1, EIF2AK3 | ACE 4590/4885DPP4 3318/4885PREP 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.